Healthcare / Medical DevicesStockholm
$3.68
-0.04 (-0.93%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-63.9M · quality 51.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$115M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-59.7%
↓Gross Margin
62.4%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+40.8%
FCF CAGR
—
FCF margin
-205.9%
FCF / Net income
0.87x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $17.5M · net income $-41.6M · FCF $-36.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $17.5M | $17.5M | $18.8M | $8.3M | $6.3M |
| Net Income | $-41.6M | $-41.6M | $-47.6M | $-79.8M | $-70.7M |
| EBITDA | $-39.4M | $-39.4M | $-44.8M | $-68.4M | $-57.8M |
| EPS | -1.60 | -1.60 | -4.30 | -11.51 | -163.22 |
| Gross Margin | 62.4% | 62.4% | 55.5% | 36.2% | -44.5% |
| Operating Margin | -164.7% | -164.7% | -288.8% | -791.5% | -1075.9% |
| Net Margin | -238.0% | -238.0% | -253.5% | -964.5% | -1127.3% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.00 | 0.01 | 3.33 |
| Current Ratio | 2.91 | 2.91 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-36.0M | $-36.0M | $-63.9M | $-72.0M | $-82.1M |
| Returns | |||||
| ROE | -59.7% | -59.7% | -69.3% | -174.3% | -766.6% |
| Valuation | |||||
| P/B | 1.37 | 1.37 | 1.05 | 4.24 | 2.32 |
| Growth & Yield | |||||
| Revenue Growth | -6.9% | -6.9% | 127.0% | 32.0% | — |
| EPS Growth | 62.8% | 62.8% | 62.6% | 92.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+24.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-4.30 → -1.60
Residual
+24.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.